Authors:
MJ Sale, E Minihane, NR Monks, R Gilley, FM Richards, KP Schifferli, CL Andersen, EJ Davies, MA Vicente, E Ozono, A Markovets, JR Dry, L Drew, V Flemington, T Proia, DI Jodrell, PD Smith, SJ Cook
Journal name: 
Nat Commun
Citation info: 
10(1):5167
Abstract: 
BRAF and MEK1/2 inhibitors are effective in melanoma but resistance inevitably develops. Despite increasing the abundance of pro-apoptotic BIM and BMF, ERK1/2 pathway inhibition is predominantly cytostatic, reflecting residual pro-survival BCL2 family activity. Here, we show that uniquely low BCL-XL expression in melanoma biases the pro-survival pool towards MCL1. Consequently, BRAF or MEK1/2 inhibitors are synthetic lethal with the MCL1 inhibitor AZD5991, driving profound tumour cell death that requires BAK/BAX, BIM and BMF, and inhibiting tumour growth in vivo. Combination of ERK1/2 pathway inhibitors with BCL2/BCL-w/BCL-XL inhibitors is stronger in CRC, correlating with a low MCL1:BCL-XL ratio; indeed the MCL1:BCL-XL ratio is predictive of ERK1/2 pathway inhibitor synergy with MCL1 or BCL2/BCL-w/BCL-XL inhibitors. Finally, AZD5991 delays acquired BRAFi/MEKi resistance and enhances the efficacy of an ERK1/2 inhibitor in a model of acquired BRAFi + MEKi resistance. Thus combining ERK1/2 pathway inhibitors with MCL1 antagonists in melanoma could improve therapeutic index and patient outcomes.
DOI: 
http://doi.org/10.1038/s41467-019-12409-w
Research group: 
Jodrell Group
E-pub date: 
31 Oct 2019
Users with this publication listed: 
Duncan Jodrell
Fran Richards